$-0.01
(Market cap
$91 Mln
Recently Viewed
Clear AllMarket cap
$91 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
4.9
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-1.6 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-1.5
Debt to Equity
0
Book Value
$0.6
EPS
$-0.6
Face value
--
Shares outstanding
42,488,578
CFO
$-51.78 Mln
EBITDA
$-60.02 Mln
Net Profit
$-60.63 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Gain Therapeutics (GANX)
| -34.2 | 11.6 | 17.1 | 17.8 | -24.7 | -31.4 | -- |
|
BSE Sensex*
| -6.4 | 6.4 | -3.5 | 0.9 | 10.0 | 10.7 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Gain Therapeutics (GANX)
| 49.1 | -33.6 | 4.3 | -42.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Gain Therapeutics (GANX)
|
2.1 | 90.5 | 0.0 | -20.2 | -- | -155.7 | -- | 4.9 |
| 69.3 | 9,733.6 | 1,091.0 | 202.3 | 31.6 | 31.3 | 43.4 | 17.1 | |
| 66.1 | 8,216.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.6 | 11,658.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.1 | 5.3 | |
| 91.1 | 11,852.6 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 69.6 | 8,209.1 | 1,396.6 | 316.9 | 59.8 | 153.6 | 27.1 | 161.7 | |
| 527.1 | 12,204.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.3 | |
| 528.4 | 14,867.3 | 2,530.2 | 451.1 | 21.3 | 70.2 | 34 | 32.4 | |
| 108.2 | 8,460.0 | 0.0 | -425.4 | -- | -36.7 | -- | 6.8 | |
| 342.6 | 9,538.9 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers... novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland. Read more
Founder & Chairman
Dr. Khalid Islam Ph.D.
Founder & Chairman
Dr. Khalid Islam Ph.D.
Headquarters
Bethesda, MD
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Gain Therapeutics Inc (GANX) is $2.12 (NASDAQ) as of 20-Apr-2026 16:00 EDT. Gain Therapeutics Inc (GANX) has given a return of -24.72% in the last 3 years.
Since, TTM earnings of Gain Therapeutics Inc (GANX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-5.27
|
5.72
|
|
2024
|
-2.43
|
6.77
|
|
2023
|
-1.91
|
3.37
|
|
2022
|
-2.14
|
1.99
|
|
2021
|
-3.91
|
1.56
|
The 52-week high and low of Gain Therapeutics Inc (GANX) are Rs 4.34 and Rs 1.41 as of 21-Apr-2026.
Gain Therapeutics Inc (GANX) has a market capitalisation of $ 91 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Gain Therapeutics Inc (GANX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.